-
1 Comment
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Other sector with a price to sales ratio of 0.0.
Based on the above factors, Kronos Bio, Inc gets an overall score of 1/5.
| Sector | Healthcare |
|---|---|
| Industry | Biotechnology |
| Exchange | NASDAQ |
| CurrencyCode | USD |
| ISIN | US50107A1043 |
| Beta | 1.79 |
|---|---|
| Market Cap | 54M |
| PE Ratio | None |
| Target Price | 2.25 |
| Dividend Yield | None |
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics to treat cancer and other serious diseases in the United States. It is developing KB-9558, a p300 KAT inhibitor development candidate which is in preclinical development for the treatment of multiple myeloma, as well as HPV-driven tumors; and KB-7898, a p300 KAT inhibitor, which is in preclinical development for the treatment of Sjogren's disease. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for KRON using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
